Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.009
Neutral
RSI(14)
39.124
Neutral
STOCH(KDJ)(9,3,3)
36.896
Sell
ATR(14)
0.380
Low Volatility
CCI(14)
-143.762
Sell
Williams %R
94.815
Oversold
TRIX(12,20)
-0.011
Sell
StochRSI(14)
0.000
Sell
LENSAR Inc
LNSR11.440USD
-1.080-8.63%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
136.51MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of LENSAR Inc
Currency: USD Updated: 2025-11-06Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
LENSAR Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Hold
Current Rating
15.000
Target Price
+19.81%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
LENSAR Inc Highlights
StrengthsRisks
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 51.29% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 53.49M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 53.49M.
Fairly Valued
The company’s latest PE is -2.72, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 5.68M shares, increasing 2.65% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 563.58K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.07.
Financial Health
Currency: USD Updated: 2025-11-06The company's current financial score is 6.97, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 13.94M, representing a year-over-year increase of 10.28%, while its net profit experienced a year-over-year increase of 80.49%.
Score
Financials
4.27
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
9.72
Operational Efficiency
7.90
Growth Potential
5.79
Shareholder Returns
7.16
LENSAR Inc's Company Valuation
Currency: USD Updated: 2025-11-06The company’s current valuation score is 6.73, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -2.72, which is -58.97% below the recent high of -1.12 and -127.21% above the recent low of -6.19.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 118/210
No Data
Earnings Forecast
Currency: USD Updated: 2025-11-06The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for LENSAR Inc is 15.00, with a high of 15.00 and a low of 15.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
2
analysts
Hold
Current Rating
15.000
Target Price
+19.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
89
Total
4
Median
7
Average
Company name
Ratings
Analysts
LENSAR Inc
LNSR
2
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-06The company’s current price momentum score is 6.28, which is lower than the Healthcare Equipment & Supplies industry's average of 6.74. Sideways: Currently, the stock price is trading between the resistance level at 12.32 and the support level at 10.97, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
12.184
Sell
MA10
12.057
Sell
MA20
12.021
Sell
MA50
12.170
Sell
MA100
12.505
Sell
MA200
12.780
Sell
Institutional Confidence
Currency: USD Updated: 2025-11-06The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 47.60%, representing a quarter-over-quarter decrease of 27.73%. The largest institutional shareholder is Brandes Investmen, holding a total of 563.58K shares, representing 4.72% of shares outstanding, with 12.47% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
North Run Capital, LP
Curtis (Nicholas T)
Link (William J)
BlackRock Institutional Trust Company, N.A.
Connaughton (Alan B.)
La Française AM
Lindstrom (Richard L)
1
2
Risk Assessment
Currency: USD Updated: 2025-11-06The company’s current risk assessment score is 5.25, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.64. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.64
VaR
+5.56%
240-Day Maximum Drawdown
+32.19%
240-Day Volatility
+66.21%
Return
Best Daily Return
60 days
+3.63%
120 days
+3.63%
5 years
+19.60%
Worst Daily Return
60 days
-8.63%
120 days
-8.63%
5 years
-18.77%
Sharpe Ratio
60 days
-1.44
120 days
-1.43
5 years
+0.51
Risk Assessment
Maximum Drawdown
240 days
+32.19%
3 years
+54.83%
5 years
+78.97%
Return-to-Drawdown Ratio
240 days
+1.78
3 years
+1.88
5 years
+0.18
Skewness
240 days
+1.25
3 years
+0.22
5 years
+0.40
Volatility
Realised Volatility
240 days
+66.21%
5 years
+83.43%
Standardised True Range
240 days
+4.61%
5 years
+3.23%
Downside Risk-Adjusted Return
120 days
-182.76%
240 days
-182.76%
Maximum Daily Upside Volatility
60 days
+19.25%
Maximum Daily Downside Volatility
60 days
+24.35%
Liquidity
Average Turnover Rate
60 days
+0.82%
120 days
+1.13%
5 years
--
Turnover Deviation
20 days
-7.46%
60 days
+46.02%
120 days
+101.39%
Peer Comparison
Healthcare Equipment & Supplies
LENSAR Inc
LNSR
6.03 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
CSTL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
COR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
